Wyeth Licenses Drug Targets From Galapagos

Wyeth has licensed three bone anabolic drug targets from a 2003 research agreement in osteoporosis with Galapagos, resulting in a 1.05 million Euro milestone payment to the Belgium-based drug firm.
Pharmaceutical Business Review